ECTE Operating in Booming $11 Billion Plus Market






        

 

 
Demand for Diabetes Monitoring and Therapies is booming…because the number of Type 1 and Type 2  Diabetic Patients is increasing dramatically.
One study that analysed the $11 billion U.S. Diabetes monitoring product and therapy industry stated, "US demand for diabetes monitoring products and therapies is expected to grow 9.5 percent annually through 2008.  Gains will be driven by more diabetes patients and more aggressive treatments."
Furthermore, it indicated that there were 24 major players including:

Eli Lilly
GlaxoSmithKline
Bristol-Myers Squibb
Johnson & Johnson
Sanofi-Aventis
Roche
Bayer
Abbott Laboratories
Novo Nordisk
Medtronic MiniMed

Now, let me ask you something…do you recognize any of these major pharmaceutical companies?  
Another question…do you think any of these major players could be interested in acquiring a potential threat within its segment that is poised to penetrate their current multi-million dollar, highly profitable market share?
Well, it’s just food for thought.

But understand that Roche Diagnostics was the overall market leader at one point with a 34% share of the blood glucose meter market.  I highly doubt company insiders at Roche…or Johnson & Johnson which has been #2 in market share… like the idea of a threat. 

Soooooo, if you can’t beat ‘em… buy ‘em!


Just remember that this is a big market with a big need…

        Top 2 Factors Fueling Multi-Billion Dollar Diabetes Monitoring Market

(1) the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in SKYROCKETING rates of diabetes among adults across the world

(2) frequent monitoring can greatly reduce serious and even fatal consequences of uncontrolled blood glucose levels in patients

 Hence, the growing number of Americans diagnosed with diabetes – estimated to climb to 14.5 million in 2008.

                         ———————————————–

                                        Critical Care Market Opportunity

  • Initial critical care and hospital market opportunities greater than $1 Billion which includes 6,000 hospitals in the U.S alone with 120,00 critical care hospital beds. 

  • ECTE’s needle-free continuous monitoring system could be offered at a competitive price point directly to patients

  • ECTE is positioned to be "first-to-market" with their system

  • Additional upside potential and partnership possibilities create multi-billion dollar opportunities with general population use

 

                      —————————————————–

Overall, ECTE creates a compelling trade idea!
The Company has completed 6 clinical studies of its Symphony SkinPrep System and one-piece tCGM Biosensor that resulted in positive results. 

                 The Symphony Pilot Studies Concluded the Following:

  • Symphony is effective at monitoring BG!
  • Symphony data strongly correlate with existing hospital BG measurements!
  • Symphony accuracy superior to handheld glucometers!
  • Symphony is reliable with NO failures during studies!
  • No safety concerns identified!
                          ——————————————-

Traders should certainly perform their due diligence on ECTE and the market opportunity presented.  Like I mentioned earlier, ECTE could be one of the rare long term trade ideas.
                          Why ECTE Could Be Longer Term Invesment Opportunity
#1.  ECTE could be an acquisition target
#2.  ECTE expects to receive the following from its Ferndale Deal…

 

- $750k upfront

- $750k upon FDA approval

- $12.5mn in milestones and guaranteed minimum royalty payments

- Double digit royalty on net sales of product

- Ferndale pays all product development expenses for Prelude completion

 

#3.  ECTE has licensed its technology in South Korea to Handok Pharmaceuticals

#4.  ECTE’s expected achievements over the next 12 months also includes:

- Complete critical care study with commercial Symphony system
- Complete clinical trial of Prelude with lidocaine 
- File 510k for FDA approval of Prelude lidocaine product
- FDA approval of Prelude lidocaine product

- Begin manufacturing scale-up for validation and product launch

- File PMA with US FDA
- FDA approval of Symphony
- Gain AMEX or Nasdaq listing
- Complete strategic partner licensing deals
- Prepare company for potential acquisition

#5.  ECTE has solid Strategic Partnerships, Licensing Transactions and Strong IP Portfolio…

                                
                           —————————————

ECTE has – based upon my research – one or two more potential FDA Approval’s anticipated that could generate high demand for shares. 

That’s because it could enable ECTE to sell their technology more aggressively and begin market penetration. 

 *** Have you ever owned shares of a stock prior to a Major FDA approval??? ***
                    
                        ——————————————-

Keep a close watch on ECTE!
The symbol witnessed increased price on higher volume on Friday which could be a great indication of what could occur going forward.
Besides, you cannot ask for a more bullish indication.
With so many of the fundamental and technical aspects of ECTE being in the positive, this could be one of the few stocks that have more long term investment appeal for traders relative to the swing trade ideas that I more frequently present.
 
 
 
Best Regards,
 
 
 
 
 
 
 
 
 
 
 
 
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. ****************************************************************************************************************** The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: The PennyStockMoneyTrain employees are not Registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read at http://www.pennystockmoneytrain.com/disclaimer Release of Liability: Through use of this website viewing or using you agree to hold PennyStockMoneyTrain, its operators owners and employees harmless and to compltely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or
otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. PennyStockMoneyTrain’s affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. PennyStockMoneyTrain encourages readers and investors to supplement the information in these reports with independent research and other pro advice. PennyStockMoneyTrain has agreed to be compensated one hundred fifty thousand dollars for a one month investor awareness program by a third party for ECTE. All information on featured companies is provided by the companies profiled, or is available from public sources and PennyStockMoneyTrain makes no
representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. This is not a solicitation to or sell any securities. Any claims or Statements should be deemed apocryphal. PennyStockMoneyTrain, nor any of its affiliates are not registered investment advisors or a broker dealers.




This message was sent from PennyStockMoneyTrain.com to Subscriber. It was sent from: PennyStockMoneyTrain.com, 12740 Hillcrest Rd. Suite 265, Dallas, TX 75230. You can modify/update your subscription via the link below.

Email Marketing by
iContact - Try It Free!